Press release no. 6/2024 - A meeting convened by AIFA's Technical-scientific Director, Pierluigi Russo, with representatives of the Italian Endocrinology Society (SIE), the Italian Society of Andrology and Sexuality Medicine (SIAMS), and the Italian Society of Paediatric Endocrinology and Diabetology (SIEDP) was held today at the Italian Medicines Agency's headquarters.

As part of the meeting, the scientific societies were asked, following a review of the scientific literature, to list the clinical studies that have evaluated the use of triptorelin in the treatment of gender dysphoria, i.e. the indications found in the main guidelines.
The Technical-scientific director Director also asked whether, compared to the evidence dating back to 2017 produced by the same societies as part of the proceedings carried out pursuant to Law 648/1996, further experimental and clinical evidence had been published in the meantime.

Awaiting the feedback from the scientific societies, it should be noted that this call and verification by AIFA is part of the ordinary process of evaluation of the evidence available in relation to the off-label use reimbursed by the National Health Service.